ABCL (AbCellera Biologics) Beneish M-Score: -0.70 (As of Jun. 27, 2026)


ABCL AbCellera Biologics Inc ABCL
59 GF Score
Price $7.38
GF Value $5.62
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is AbCellera Biologics Beneish M-Score?

AbCellera Biologics ABCL +10.81% 59 Beneish M-Score is -0.70 as of Jun. 27, 2026. GuruFocus rates ABCL with a GF Score™ of 59/100 and a GF Value™ of $5.62 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 831 Biotechnology companies, AbCellera Biologics ranks worse than 80.02% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.7 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for AbCellera Biologics's Beneish M-Score or its related term are showing as below:

ABCL' s Beneish M-Score Range Over the Past 10 Years
Min: -4.04   Med: -1.93   Max: 10.52
Current: -0.7

During the past 8 years, the highest Beneish M-Score of AbCellera Biologics was 10.52. The lowest was -4.04. And the median was -1.93.


AbCellera Biologics Beneish M-Score Historical Data

* Premium members only.

The historical data trend for AbCellera Biologics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbCellera Biologics Beneish M-Score Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial -2.72 -3.12 0.47 -2.40 -1.29

AbCellera Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.88 -1.96 -1.47 -1.29 -0.70

ABCL vs SRPT, RAPP, RXRX: Beneish M-Score Comparison

For the Biotechnology subindustry, AbCellera Biologics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbCellera Biologics Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's Beneish M-Score falls into.


ABCL
59GF Score
AbCellera Biologics Inc ABCL
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbCellera Biologics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of AbCellera Biologics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.2667+0.528 * 1+0.404 * 0.9734+0.892 * 3.4266+0.115 * 3.2056
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.2663+4.679 * 0.007259-0.327 * 1.3474
=-0.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $115.73 Mil.
Revenue was 8.315 + 44.853 + 8.955 + 17.084 = $79.21 Mil.
Gross Profit was 8.315 + 44.853 + 8.955 + 17.084 = $79.21 Mil.
Total Current Assets was $664.60 Mil.
Total Assets was $1,307.11 Mil.
Property, Plant and Equipment(Net PPE) was $422.81 Mil.
Depreciation, Depletion and Amortization(DDA) was $30.87 Mil.
Selling, General, & Admin. Expense(SGA) was $76.50 Mil.
Total Current Liabilities was $47.29 Mil.
Long-Term Debt & Capital Lease Obligation was $134.31 Mil.
Net Income was -43.165 + -8.945 + -57.119 + -34.727 = $-143.96 Mil.
Non Operating Income was 0 + -0.153 + -1.984 + 1.957 = $-0.18 Mil.
Cash Flow from Operations was -33.523 + -34.743 + -52.594 + -32.404 = $-153.26 Mil.
Total Receivables was $126.61 Mil.
Revenue was 4.235 + 5.05 + 6.507 + 7.323 = $23.12 Mil.
Gross Profit was 4.235 + 5.05 + 6.507 + 7.323 = $23.12 Mil.
Total Current Assets was $764.98 Mil.
Total Assets was $1,344.21 Mil.
Property, Plant and Equipment(Net PPE) was $347.10 Mil.
Depreciation, Depletion and Amortization(DDA) was $96.84 Mil.
Selling, General, & Admin. Expense(SGA) was $83.84 Mil.
Total Current Liabilities was $75.40 Mil.
Long-Term Debt & Capital Lease Obligation was $63.21 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(115.725 / 79.207) / (126.614 / 23.115)
=1.461045 / 5.477569
=0.2667

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(23.115 / 23.115) / (79.207 / 79.207)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (664.596 + 422.806) / 1307.112) / (1 - (764.978 + 347.102) / 1344.208)
=0.168088 / 0.172688
=0.9734

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=79.207 / 23.115
=3.4266

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(96.837 / (96.837 + 347.102)) / (30.871 / (30.871 + 422.806))
=0.218131 / 0.068046
=3.2056

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(76.497 / 79.207) / (83.842 / 23.115)
=0.965786 / 3.627169
=0.2663

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((134.309 + 47.294) / 1307.112) / ((63.21 + 75.396) / 1344.208)
=0.138935 / 0.103114
=1.3474

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-143.956 - -0.18 - -153.264) / 1307.112
=0.007259

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

AbCellera Biologics has a M-score of -0.70 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -0.70 mean?
AbCellera Biologics (ABCL) has a Beneish M-Score of -0.70 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on AbCellera Biologics and its competitors. According to the industry distribution chart, AbCellera Biologics ranks #665 out of 831 companies in the Biotechnology industry, placing it in the top 80%.
Is AbCellera Biologics' Beneish M-Score too high?
AbCellera Biologics' current Beneish M-Score is -0.70. Based on the distribution chart, AbCellera Biologics ranks #665 out of 831 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Beneish M-Score compare to SRPT and RAPP?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #665 out of 831 companies for Beneish M-Score. This places AbCellera Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on AbCellera Biologics and its competitors. AbCellera Biologics's current Beneish M-Score is -0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.62, compared to a current price of $7.38 — trading 31.3% above its estimated fair value. The current Beneish M-Score is -0.70. AbCellera Biologics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Beneish M-Score is -0.70 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbCellera Biologics (ABCL) Overvalued in 2026?

Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued. The current stock price of $7.38 is trading 31.3% above its estimated GF Value™ of $5.62. GuruFocus considers AbCellera Biologics to be Significantly Overvalued.

Key valuation signals for ABCL:

  • Beneish M-Score: -0.70
  • GF Value™: $5.62 vs. price of $7.38 (31.3% above fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AbCellera Biologics Business Description

Other Exchanges 8QQ:Germany
Address 150 W 4th Avenue, Vancouver, BC, CAN, V5Y 1G6
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score

Get the complete analysis for ABCL

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.38
Price
$5.62
GF Value